Another Reason to Love Pecans

The American Heart Association Certifies Pecans As Heart-Healthy Food

 

 

View all images

 
Download image

 
Download image

ATLANTA, Aug. 2, 2012  /PRNewswire/ -- Pecans are now designated as heart-healthy when enjoyed as part of a healthy eating pattern by the American Heart Association's Heart-Check Certification Program (www.heartcheckmark.org), according to the National Pecan Shellers Association (NPSA). Unroasted and unsalted pecan halves and pieces can now carry the Heart-Check mark to notify consumers that they meet the program's nutritional guidelines, including criteria for saturated fat and sodium. 

Dr. Rachel Johnson , Ph.D., R.D., the Bickford Green and Gold Professor of Nutrition at the University of Vermont and an American Heart Association spokesperson said, "We know that consumers have relied on the American Heart Association's Heart-Check mark to easily identify heart-healthy foods for more than 15 years. Adding nuts, fish and other foods that are rich sources of good fats, monounsaturated and polyunsaturated fats, enhances the program and gives more healthy options consumers can choose from with the same trust factor."

"Pecans stay with you longer than high carbohydrate snacks that your body burns through quickly," said Vickie Mabry , NPSA Executive Director.  "With antioxidants as well as a tender texture, rich buttery flavor and gentle crunch, pecans make an ideal snack choice for everyone," she added.

Heart-Check Mark            The American Heart Association's HeartCheck Food Certification Program was launched in 1995 to help grocery shoppers quickly and easily identify heart-healthy foods that can be incorporated into a sensible eating pattern. In order to earn this designation, nuts must meet certain nutritional requirements for saturated fat, trans fat, cholesterol, sodium and beneficial nutrients.  Today, the red and white heart-healthy symbol has become the one of the most trusted and well-known nutrition icons representing heart-healthy eating. 

Health Benefits of Pecans*

Findings from a 2001 study conducted at Loma Linda University¹ showed that adding just a handful of pecans to your diet each day may help inhibit unwanted oxidation of blood lipids, thus helping prevent coronary heart disease.   Pecans also offer many other health benefits:

• CholesterolPecans also play a role in reducing the risk of heart disease because they have an abundance of "good" heart healthy fats.  These unsaturated fats can have a protective effect by lowering total blood cholesterol when eaten in moderation.  Pecans contain no cholesterol and no trans-fat. 
• VitaminsPecans contain more than 19 vitamins and minerals – including vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, several B vitamins and zinc. One ounce of pecans provides 10 percent of the recommended Daily Value for fiber. Pecans are also a natural, high-quality source of protein that contains very few carbohydrates and no cholesterol and are naturally sodium-free. 

Ways to Incorporate Pecans into a Healthy Lifestyle

Pecans are easy to add to your eating plan; simply grab a handful!  Pecans are healthy and delicious, and just a one-ounce serving (15- 20 pecan halves) packs more than 19 vitamins and minerals, fiber and protein to keep you going.  They're a perfect snack for both children and adults.   

Often associated with indulgences and occasional treats, pecans can also be eaten in healthier forms and cooked or baked in a wide variety of foods to add flavor and nutrition.  Delicious recipes can be found or created using pecans for breakfast, salads, entrees and side dishes.*

Pecan recipes and downloadable images of foods incorporating pecans can be found at www.ilovepecans.org.*

ABOUT THE NATIONAL PECAN SHELLERS ASSOCIATION                     The National Pecan Shellers Association (NPSA), a non-profit trade association, is committed to educating culinary and health professionals, food technologists and the general public about the nutritional benefits, variety of uses and all around great taste of pecans. For more information on the health benefits of pecans and where to find them, visit www.ilovepecans.org.*

PR Newswire (http://s.tt/1rFyL)

Elekta y Brainlab colaboran para aumentar la precisión y la comodidad de los tratamientos de radiocirugía

 

 

FELDKIRCHEN, Alemania, August 2, 2012 /PRNewswire/ --

El Instituto de investigación Fortis Memorial de Gurgaon (India) instala el primer sistema de tratamiento de Elekta equipado con el sistema integrado de posicionamiento del paciente ExacTrac de Brainlab

Brainlab y Elekta, líderes en el tratamiento contra el cáncer, han anunciado la primera instalación de un acelerador lineal de Elekta equipado con el sistema de posicionamiento del paciente ExacTrac^® de Brainlab; una estrategia que permitirá mejorar la precisión y comodidad de los tratamientos de radiocirugía en pacientes con cáncer. Se planea integrar ExacTrac en dos aceleradores lineales de Elekta en el Instituto de investigación Fortis Memorial de Gurgaon (India).

"ExacTrac es un sistema de radioterapia guiada por imagen rápido, intuitivo y muy preciso que, en combinación con nuestro avanzado sistema de tratamiento Elekta, nos brinda la oportunidad de maximizar los beneficios de ambos sistemas en los pacientes", afirma el Dr. Ashok V. Chordiya , director territorial del Instituto de investigación Fortis Memorial de Gurgaon.

Con más de 500 instalaciones por todo el mundo, ExacTrac es un sistema de eficacia comprobada que facilita el posicionamiento submilimétrico de pacientes con tumores en el cerebro y en el cuerpo. El sistema proporciona una valiosa solución conocida como radiocirugía sin marco. ExacTrac ayuda a reducir los errores en el proceso de tratamiento y maximiza potencialmente la precisión en general.

"En nuestra investigación para mejorar la accesibilidad a tratamientos alternativos de alta precisión que fueran menos invasivos, necesitábamos la colaboración de un compañero con objetivos comunes", comentó Thomas Kraft , presidente de RoW/Japan, Brainlab. "En Elekta encontramos a ese socio, que cuenta con una avanzada plataforma de tratamiento y goza de gran prestigio. Juntos seguiremos esforzándonos por conseguir una eficiencia óptima, un flujo de trabajo integrado y una atención al paciente mejorada."

Bill Yaeger , vicepresidente ejecutivo de Elekta Oncology, comentó:

"Creemos que la tecnología debería basarse en estándares de la industria y sistemas abiertos, ya que los hospitales usan distintos tipos de soluciones técnicas. Con ExacTrac, los clientes podrán elegir la solución que mejor se adapte a su propio flujo de trabajo y a sus necesidades de atención al paciente. El flujo de trabajo estereotáxico entre ambos sistemas permite un flujo de trabajo rápido y eficaz para el posicionamiento del paciente."

Fortis Healthcare Ltd., con una base de activos en diez países, es un proveedor líder e integrado de atención médica en la región de Asia y el Pacífico. La instalación del acelerador lineal combinado denota su dedicación al desarrollo continuo del sector sanitario.

Acerca de Brainlab

Brainlab desarrolla, fabrica y comercializa tecnología médica mediante software con el objetivo de optimizar los tratamientos del paciente. Sus productos principales giran en torno a una tecnología de cirugía guiada por imagen menos invasiva, una radioterapia más precisa y efectiva, y la integración, mediante sistemas de planificación y colaboración, que une a los médicos con los datos del paciente. http://www.brainlab.com

Acerca de Elekta

Elekta es una compañía pionera dedicada a la atención sanitaria de cuyos laboratorios han salido importantes innovaciones y soluciones clínicas para el tratamiento del cáncer y las enfermedades cerebrales. Esta compañía desarrolla innovadores sistemas de planificación de tratamiento y modernas herramientas de radioterapia y radiocirugía, así como sistemas de software para la mejora del flujo de trabajo en toda la gama de tratamientos del cáncer. El objetivo de Elekta es mejorar, prolongar y salvar la vida de los pacientes a través de sus productos y servicios. Las soluciones de Elekta en oncología y neurocirugía se utilizan en más de 5000 hospitales en todo el mundo. Diariamente, se diagnostica, trata o efectúa el seguimiento a más de 100000 pacientes con la ayuda de una solución del Grupo Elekta. Elekta, con sede social en Estocolmo, Suecia, da trabajo a aproximadamente 3300 personas en todo el mundo.

® Brainlab es una marca registrada en Alemania y en Estados Unidos

PR Newswire (http://s.tt/1jJJf)

Parents' Passionate Efforts Help Researchers Identify Cause Of Rare Disorder Affecting 800 Worldwide

Grass roots, down-to-the-wire, against-all-odds victory Nov. 2010 in the Pepsi Refresh $250K grant contest leads to University research collaboration that identified the genetic cause of Alternating Hemiplegia of Childhood. The find gives parents new hope for a cure.

 

 

LIVONIA, Mich., Aug. 2, 2012 /PRNewswire/ -- Alternating hemiplegia of childhood (AHC), a rare disorder that causes sporadic paralysis of the limbs and a range of other developmental challenges, has recently been given hope for a cure. Thanks to a grant in 2010 by the Pepsi Refresh Project and parental involvement throughout, a collaborative effort of prominent researchers at both Duke University and the University of Utah has resulted in identifying one of the key causes of the disorder – mutations in the gene ATP1A3. Results of this finding were recently published in the peer reviewed journal Nature Genetics.

AHC is found in less than 800 people worldwide. Experts believe that many more patients are affected by its symptoms, but are misdiagnosed due to lack of doctor knowledge of the disorder. While symptoms vary, AHC patients can also experience debilitating muscle contractions, developmental delays, trouble walking and seizures, among other challenges. The disorder typically begins prior to 18 months of age but despite the name, usually lasts throughout one's life.

According to Dr. Sandra P. Reyna , Research Associate Professor in the Department of Neurology at the University of Utah and co-author of the study, "This disorder was identified as a disease over four decades ago, but little progress had been made in understanding the causes of AHC or in identifying effective treatments."

Founded in 1993, the AHC Foundation is a non-profit, parent led organization. With such a small parent base, fundraising to finance critical research into the cause of the disorder has been a continuing challenge.

Fortunately in 2010, PepsiCo unveiled The Pepsi Refresh Project in which they awarded $20 million in grants to individuals, businesses and non-profit organizations that promote a new idea that has a positive impact on their community, state, or the nation. Each month competing organizations worked to get votes for their cause. The two organizations with the most votes each month received $250,000.

"We knew this was our chance to get enough money to make a difference," said Jeff Wuchich , father of a child with AHC and president of the AHCF. "So we worked tirelessly to get people to vote each day for the foundation to win the grant. We had parents, doctors, school organizations, hospitals and friends of families all come together on the phones and online. Our supporters walked the streets, going into grocery stores, libraries and coffee shops to ask people to vote for our cause."

As the foundation competed against larger, well known organizations like the Humane Society and Cystic Fibrosis, the team forged ahead. In a close competition the AHCF dropped to third place during the final days of the competition. With only 30 minutes remaining to vote, AHCF climbed back into the number two position and remained there until voting closed and received the $250,000 grant.

"It was a really great experience to witness all of these people banding together for such a great cause," said Wuchich. "We proved that day that while we may be small, we are a mighty and determined community."

Experts say identifying the genetic mutation is a critical first step. According to Dr. Kathryn J. Swoboda , Associate Professor of Neurology and Director of the Pediatric Motor Disorders Research Program at the University of Utah, "The discovery of this mutation provides an exciting new opportunity to develop targeted treatments to help patients with this rare and devastating disorder."

Dr. Mohamad Mikati speaking for the Duke research group that included Dr. David Goldstein , Dr. Erin Heinzen , Dr. Mikati and many others said: "This study is an excellent example of how world-wide collaborative research can make a dramatic difference for a rare disorder as AHC. This discovery clarifies the cause the disease, provides a test that could help in its diagnosis and gives hope for the future development of an effective treatment. We are now all looking forward to working together on the next phases of the work that will bring us even closer to such effective therapies."

The AHC Foundation plans to be side by side with the experts as parents continue to identify creative ways to fund the research needed to develop these targeted treatments.

"My son Matthew and other AHC patients like him depend on donations to extend research and to educate doctors about the disorder," said Wuchich. "As parents, we won't stop until we find a treatment and a cure."

For more information and to donate time or money, visit ahckids.org. AHCF can also be found on Facebook and Twitter.

SOURCE AHCkids.org

PR Newswire (http://s.tt/1jJGB)

BD Announces Results For 2012 Third Fiscal Quarter

-- Reported results reflect reclassification of Discovery Labware unit as discontinued operations, excluding Advanced Bioprocessing.

-- Third-quarter earnings per share of $1.59 include $1.52 from continuing operations and $0.07 from discontinued operations relating to the Discovery Labware unit.

 

 

FRANKLIN LAKES, N.J., Aug. 2, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.981 billion for the third fiscal quarter ended June 30, 2012, representing an increase of 1.5 percent from the prior-year period, or 4.9 percent on a foreign currency-neutral basis. 

"We are very pleased with our third quarter results," said Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President. "As we anticipated, our revenue and earnings growth improved this quarter, demonstrating that our strategy implementation is on track and in line with our previously communicated expectations."

Update on Agreement to Sell Discovery Labware Unit, Excluding Advanced Bioprocessing

In April 2012, the Company signed a definitive agreement to sell its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platform. The transaction is expected to be completed by the end of calendar year 2012, subject to the satisfaction of customary closing conditions, including consultations and regulatory approvals. The results of operations associated with this disposal group have been reclassified as discontinued operations for all quarters and years referred to in this release.

As illustrated on page 3 of the attached financial tables, diluted earnings per share for the third quarter of $1.59 less the $0.07 from discontinued operations resulted in earnings per share from continuing operations of $1.52.

Also included for reference in the attached financial tables are the Company's Consolidated Income Statements reflecting the reclassification change of the Discovery Labware disposal group to discontinued operations, for the first two quarters of fiscal year 2012 and for all periods in fiscal year 2011.

Third Quarter and Nine-Month Fiscal 2012 Operating Results

Reported diluted earnings per share from continuing operations for the third quarter were $1.52, representing an increase of 5.6 percent over the prior-year period. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the third quarter increased by 9.7 percent.

For the nine-month period ending June 30, 2012, reported diluted earnings per share from continuing operations were $3.95, representing a decrease of 1.7 percent over the prior- year period.  On a foreign currency-neutral basis, diluted earnings per share from continuing operations increased by 1.0 percent for this period.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.070 billion, representing an increase of 2.4 percent compared with the prior-year period, or 6.4 percent on a currency-neutral basis. The segment's revenue growth reflected strong sales and favorable comparisons in the Diabetes Care and Pharmaceutical Systems units. For the nine-month period ended June 30, 2012, BD Medical revenues increased 3.0 percent, or 4.8 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $642 million, representing an increase of 1.7 percent compared with the prior-year period, or 4.7 percent on a foreign currency-neutral basis. The segment's growth was primarily driven by solid sales of Preanalytical Systems safety-engineered products and strong sales in the Women's Health and Cancer platform.  For the nine-month period ended June 30, 2012, BD Diagnostics revenues increased 3.0 percent, or 4.3 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $268 million, representing a decrease of 2.7 percent compared with the prior-year period. On a currency-neutral basis, revenues increased by 0.2 percent.  Segment results continue to be negatively affected by weakness in the U.S. research market. For the nine-month period ended June 30, 2012, BD Biosciences revenues increased 0.2 percent, or 1.3 percent on a currency-neutral basis.

Geographic Results

Third quarter revenues in the U.S. were $837 million, representing an increase of 1.1 percent compared with the prior-year period. Revenues outside of the U.S. were $1.144 billion, representing an increase of 1.7 percent compared with the prior-year period, or an increase of 7.8 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products. For the nine-month period ended June 30, 2012, revenues in the U.S. were$2.464 billion, representing an increase of 1.3 percent compared with the prior-year period. Revenues outside of the U.S. were $3.277 billion, representing an increase of 3.6 percent compared with the prior-year period, or 6.4 percent on a foreign currency-neutral basis.

Fiscal 2012 Outlook for Full Year

The Company expects reported revenue growth for the full fiscal year 2012 to be about 1 percent versus its previously disclosed guidance of 1 to 2 percent. This reflects the anticipated effects of unfavorable currency translation. On a currency-neutral basis, the Company is raising the lower end of its previously disclosed guidance of 3 to 4 percent to about 4 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2012 to be between $5.33 and $5.38. This reflects the reclassification of the Discovery Labware unit as discontinued operations and the anticipated effects of unfavorable currency translation. On a currency-neutral basis, the Company reaffirms its previously disclosed diluted earnings per share growth guidance of 4 to 5 percent, which includes the estimated impact of our recently announced agreement to acquire Safety Syringes, Inc.

Conference Call Information

A conference call regarding BD's third quarter results and its expectations for the full fiscal year 2012 will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday August 2, 2012.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, August 9, 2012, access code 96886040.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2012 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; changes in interest or foreign currency exchange rates; competitive factors; pricing and other market pressures; our ability to successfully integrate any businesses we acquire; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:Monique N. Dolecki, Investor Relations – 201-847-5378
Colleen T. White, Corporate Communications – 201-847-5369

PR Newswire (http://s.tt/1z562)

PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals

 

 

BOSTON, Aug. 2, 2012 /PRNewswire/ --  PAREXEL Consulting, a business unit of PAREXEL International (NASDAQ: PRXL) and a leading global consultancy serving the biopharmaceutical and medical device industries, today announced that Leanne R. Larsonhas been appointed as Vice President, Evidence Development.  The new position demonstrates a continuing commitment from PAREXEL in the area of Outcomes Research. Ms. Larson's expertise in strategy, design, implementation, and analysis of patient registries and outcomes research programs will further support clients in meeting the needs of payors, regulators, physicians, and patients when making treatment decisions.

Ms. Larson has more than twenty-five years' experience in healthcare, featuring extensive work in pharmaceutical product development and marketing, and in healthcare technology and operational consulting.  For nearly twenty years, she has been an industry thought leader in developing and implementing patient registries and in advancing the science and application of outcomes research. Prior to joining PAREXEL, Ms. Larson served more than 15 years in senior and strategic roles within Clinical Research Organizations. She has also held positions in Ernst & Young's Life Sciences and Pharmaceuticals consulting practice, as well as Merck and Co.'s Health Sciences-Digestive Disease group.

" Leanne Larson is a great addition to PAREXEL. Bringing on board an industry leader of her caliber further strengthens our recognized team of experts," said Ron Kraus , Corporate Vice President & Worldwide Head of PAREXEL Consulting and Medical Communications Services.  "We eagerly look forward to applying her deep knowledge and experience to support our clients in successfully commercializing their products."

Larson received her Master of Health Administration (MHA) from Governors State University and a Bachelor of Science in Community Health from the University of Illinois. She is also an Instructor in Health Service Systems at the Keller Graduate School of Management, and is a Charter Member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), as well as an Invited Reviewer for The Center for Disease Control and Prevention (CDC).

PAREXEL Consulting provides integrated product development consulting services, helping biopharmaceutical companies shorten time to market and maintain product viability in developed and emerging markets. Expertise provided by PAREXEL Consulting includes strategic regulatory guidance, product globalization, and development optimization to effectively align development and commercialization strategies. PAREXEL Consulting experts also provide capabilities in development of leading edge products such as biosimilars, therapeutic vaccines, and combination products. For information regarding PAREXEL consulting services visit http://www.parexel.com

About PAREXEL InternationalPAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visitwww.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

PR Newswire (http://s.tt/1uO1J)